MIR150 and mantle cell lymphoma: MIR-150 is downregulated in several B-lymphocyte malignancies (49, 54–57), such as diffuse large B-cell lymphoma (DLBCL) (55), mantle cell lymphoma (MCL) (54), BL (9) and aggressive chronic lymphocytic leukemia (CLL) (11).